Novo Nordisk (NVO) Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
NVO Community Fair Values
Create NarrativeSee what 747 others think this stock is worth. Follow their fair value or set your own to get alerts.
Top Community Narratives
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 41.71 |
| 52 Week High | DKK 64.16 |
| 52 Week Low | DKK 35.12 |
| Beta | 0.34 |
| 1 Month Change | -7.06% |
| 3 Month Change | -3.43% |
| 1 Year Change | -28.33% |
| 3 Year Change | -55.97% |
| 5 Year Change | -17.30% |
| Change since IPO | 22,912.54% |
Recent News & Updates
Seeking Alpha • 3h
Novo Nordisk: Why This Corporate Rebrand Is More Than Simply PR Posturing
Summary Novo Nordisk A/S has rebranded as 'Novo' with a new strategy, aiming for greater consumer focus and operational agility amid intensifying GLP-1 competition. NVO's GLP-1 franchise faces mounting pressure from Eli Lilly's superior market share and new entrants, while pricing and regulatory challenges persist. Despite pioneering semaglutide, NVO's revenues and stock have declined, with the bull thesis undermined by competitive and operational setbacks. The rebrand and "The Novo Way" may improve consumer engagement, but a sustained stock recovery likely depends on execution and forthcoming strategic updates. Read the full article on Seeking Alpha
New Narrative • Aug 15
Fair Price 80$ eventually 100$ depending on the market share futuro
A Novo Nordisk é uma máquina de qualidade excecional (ROA de 23%, quase sem goodwill, 11% de crescimento composto durante uma década) a atravessar uma compressão de preços nos EUA que o mercado está a tratar como permanente — paga hoje 11x lucros, contra mais de 40x em 2021. tenho a ideia de que o número de doentes tratados no Ocidente multiplica por cinco ou seis até 2033, à medida que a Europa, o Canadá e a Austrália criam regimes de comparticipação — Portugal, com 2 milhões de adultos obesos e o decreto do Infarmed em preparação, é um exemplo entre muitos.Recent updates
Seeking Alpha • 3h
Novo Nordisk: Why This Corporate Rebrand Is More Than Simply PR Posturing
Summary Novo Nordisk A/S has rebranded as 'Novo' with a new strategy, aiming for greater consumer focus and operational agility amid intensifying GLP-1 competition. NVO's GLP-1 franchise faces mounting pressure from Eli Lilly's superior market share and new entrants, while pricing and regulatory challenges persist. Despite pioneering semaglutide, NVO's revenues and stock have declined, with the bull thesis undermined by competitive and operational setbacks. The rebrand and "The Novo Way" may improve consumer engagement, but a sustained stock recovery likely depends on execution and forthcoming strategic updates. Read the full article on Seeking AlphaNew Narrative • Aug 15
Fair Price 80$ eventually 100$ depending on the market share futuro
A Novo Nordisk é uma máquina de qualidade excecional (ROA de 23%, quase sem goodwill, 11% de crescimento composto durante uma década) a atravessar uma compressão de preços nos EUA que o mercado está a tratar como permanente — paga hoje 11x lucros, contra mais de 40x em 2021. tenho a ideia de que o número de doentes tratados no Ocidente multiplica por cinco ou seis até 2033, à medida que a Europa, o Canadá e a Austrália criam regimes de comparticipação — Portugal, com 2 milhões de adultos obesos e o decreto do Infarmed em preparação, é um exemplo entre muitos.Analysis Article • Jun 19
Novo Nordisk (NVO) Stock Could Be 54.5% Undervalued After Its 90 Day Rebound
Novo Nordisk (NVO) continues to draw investor attention after recent share price moves, with the stock last closing at $43.19. The company’s performance metrics now invite closer scrutiny of its valuation and growth profile. See our latest analysis for Novo Nordisk. Recent trading has been slightly softer, with a 1-day share price return of 0.76% and a 7-day share price return of 1.75%. The 90-day share price return of 18.23% contrasts with a year to date share price decline of 17.56% and a...New Narrative • May 04
One of the two dominant players in a market projected to double, and possibly triple, over the next 5 to 8 years.
Catalysts Recent success in a phase IIIa trial showed once-daily doses of oral semaglutide demonstrated a statistically significant and superior reduction in HbA1c by 0.83% versus placebo at 26 weeks for adolescents with Type II diabetes. Based on the study data, NVO intends to seek regulatory approval for oral semaglutide in adolescents aged 10 to 17 with T2D for both Rybelsus and oral Ozempic in the U.S. and the EU in the second half of the year.Narrative Update • Jan 06
Valuation reset, but the GLP-1 franchise (and optionality) remains intact
Novo Nordisk (NVO) has continued to face a tougher near-term backdrop, but the longer-term investment case remains intact. Management has narrowed 2025 guidance to 8–11% sales growth and 4–7% operating profit growth (constant exchange rates), explicitly citing intensifying competition and pricing pressure in both diabetes and obesity.New Narrative • Aug 05
A Quality Compounder Marked Down on Overblown Fears
Policy pressure: US price cuts via the IRA and executive orderSeeking Alpha • Apr 26
Novo Nordisk: Examining Tariff And Pricing Risks
Summary Novo Nordisk has a strong balance sheet and high returns on equity, but faces challenges with its next-gen weight loss drug, CagriSema. Political risks, including potential US drug price normalization and tariffs, could impact Novo's profitability significantly. Despite competition, Novo's leadership in the weight loss drug market and growth potential make it a compelling buy at $50. With a 3.8% yield and solid EPS growth, Novo could offer attractive returns, assuming manageable political risks and continued market expansion. We consider the stock a hold at $62. Read the full article on Seeking AlphaSeeking Alpha • Apr 18
Novo Nordisk: A Price Too Low To Ignore
Summary Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is disappointing results for its drug trials, though challenges like potential tariffs on Denmark, its home country, also play a part. Yet, the company's robust fundamentals, healthy outlook and attractive market multiples go in its favour, justifying a Buy rating. Read the full article on Seeking AlphaSeeking Alpha • Mar 30
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Summary Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of drugs and product candidates relative to the rival. Dear Seeking Alpha readers, you will discover whether Novo Nordisk or Eli Lilly is a more attractive stock in the long term. Read the full article on Seeking AlphaSeeking Alpha • Mar 10
Novo Nordisk: CagriSema Disappoints Again
Summary Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy, with only 61.9% on the highest dose in the REDEFINE-2 trial. The efficacy data to date suggest CagriSema has similar efficacy to Eli Lilly's tirzepatide, and much better efficacy than semaglutide. Novo Nordisk plans to start the REDEFINE-11 trial to improve the efficacy of CagriSema, aiming for higher weight loss that could beat tirzepatide and potentially match Eli Lilly's retatrutide. Eli Lilly may have the upper hand in the obesity market, but I expect Novo Nordisk to remain a formidable competitor, with multiple other shots on goal in the clinic. Read the full article on Seeking AlphaShareholder Returns
| NVO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.4% | -0.6% | -1.6% |
| 1Y | -28.3% | 45.2% | 12.1% |
Return vs Industry: NVO underperformed the US Pharmaceuticals industry which returned 45.2% over the past year.
Return vs Market: NVO underperformed the US Market which returned 12.1% over the past year.
Price Volatility
| NVO volatility | |
|---|---|
| NVO Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NVO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NVO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 66,700 | Maziar Doustdar | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NVO fundamental statistics | |
|---|---|
| Market cap | US$186.09b |
| Earnings (TTM) | US$17.97b |
| Revenue (TTM) | US$50.85b |
10.4x
P/E Ratio3.7x
P/S RatioIs NVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVO income statement (TTM) | |
|---|---|
| Revenue | DKK 329.43b |
| Cost of Revenue | DKK 59.34b |
| Gross Profit | DKK 270.09b |
| Other Expenses | DKK 153.65b |
| Earnings | DKK 116.44b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 04, 2026
| Earnings per share (EPS) | 26.33 |
| Gross Margin | 81.99% |
| Net Profit Margin | 35.35% |
| Debt/Equity Ratio | 59.4% |
How did NVO perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield45%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/16 21:34 |
| End of Day Share Price | 2026/09/16 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novo Nordisk A/S is covered by 52 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Gerhard Schwarz | Baader Helvea Equity Research |
| José Romero Herrero | Banco Santander |